HSBC Holdings’s XBiotech XBIT Stock Holding History

HSBC Holdings’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-16,921	Closed	-$48.7K	–	3196
2025 Q2	$48.7K	Buy	16,921 +937	+6%	+$2.72K	﹤0.01%	2934
2025 Q1	$51.6K	Buy	+15,984	New	+$55.1K	﹤0.01%	2898

Other funds holding XBIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

HSBC Holdings's XBIT Position: Q3 2025 in Review

HSBC Holdings sold out of XBiotech (XBIT) in Q3 2025, closing a stake of 16,921 shares — an estimated $48.7K sold.

HSBC Holdings first reported a position in XBIT in Q1 2025 and held it in 2 quarters. The position peaked at $51.6K in Q1 2025. 48 funds tracked by Wall St. Rank hold XBIT as of Q3 2025.

HSBC Holdings reported no remaining XBiotech position as of Q3 2025 after selling out during the quarter.
HSBC Holdings sold 16,921 XBiotech shares in Q3 2025, an estimated $48.7K.
HSBC Holdings first reported a position in XBiotech in Q1 2025 and held it in 2 quarters.
HSBC Holdings's XBiotech position peaked at $51.6K in Q1 2025.
48 funds tracked by Wall St. Rank held XBiotech as of Q3 2025.

Based on HSBC Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.